September 24, 2026
Breakthrough T1D Statement on Request for Information and Stakeholder Input on Islet Reclassification
September 23, 2026
Breakthrough T1D Statement on FDA Commissioner Nominee
September 21, 2026
Breakthrough T1D Statement on Congressional Diabetes Caucus Leadership Changes
August 4, 2026
Breakthrough T1D Meets with FDA and HRSA Leaders to Accelerate Access to T1D Therapies
July 31, 2026
Breakthrough T1D Submits Comments on Centers for Medicare and Medicaid Rule
June 25, 2026
Statement Regarding T1D Fund Governance
June 17, 2026
Breakthrough T1D Applauds Senate Diabetes Caucus Co-Chairs for Urging FDA Action on Deceased Donor Islets
June 7, 2026
Breakthrough T1D’s statement on Friday’s event at the ADA Scientific Sessions
May 19, 2026
Breakthrough T1D Applauds Congressional Diabetes Caucus Co-Chairs for Urging FDA Action on Deceased Donor Islets
May 12, 2026
Breakthrough T1D Statement on FDA Advisory Committee to Discuss Tzield Application for Use in Stage 3 Type 1 Diabetes